Abstract
Disruption in the endocannabinoid system in FXS is associated with social anxiety and irritability. Cannabidiol (CBD) acts as a negative allosteric modulator at presynaptic CB1 receptors, a 5HT1A agonist and a D2 partial agonist. FXS causes intellectual disability, making symptom recognition and self-report problematic. Therapeutic response must rely on objective description of change. ZYN002 is pharmaceutically manufactured transdermal CBD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
